Does the media prefer VYGR or HYPD?

In the previous week, Voyager Therapeutics had 2 more articles in the media than Hyperion DeFi. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.88 beat Voyager Therapeutics' score of 0.45 indicating that Hyperion DeFi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HYPD or KROS?

In the previous week, Hyperion DeFi had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 2 mentions for Hyperion DeFi and 1 mentions for Keros Therapeutics. Hyperion DeFi's average media sentiment score of 0.88 beat Keros Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HYPD or UNCY more profitable?

Hyperion DeFi's return on equity of -91.59% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media favor HYPD or UNCY?

In the previous week, Unicycive Therapeutics had 41 more articles in the media than Hyperion DeFi. MarketBeat recorded 43 mentions for Unicycive Therapeutics and 2 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.88 beat Unicycive Therapeutics' score of -0.20 indicating that Hyperion DeFi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Is ALXO or HYPD more profitable?

Hyperion DeFi's return on equity of -91.59% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Hyperion DeFi N/A -91.59% -73.08%

Does the media prefer ALXO or HYPD?

In the previous week, ALX Oncology and ALX Oncology both had 2 articles in the media. Hyperion DeFi's average media sentiment score of 0.88 beat ALX Oncology's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperion DeFi (HYPD) Competitors

$3.11 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.07 -0.04 (-1.25%)

As of 07/2/2026 07:55 PM Eastern

Compare

HYPD vs. VYGR, KROS, RNA, UNCY, and ALXO

Should you buy Hyperion DeFi stock or one of its competitors? MarketBeat compares Hyperion DeFi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperion DeFi include Voyager Therapeutics (VYGR), Keros Therapeutics (KROS), Avidity Biosciences (RNA), Unicycive Therapeutics (UNCY), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry.

How does Hyperion DeFi compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Hyperion DeFi has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Hyperion DeFi	N/A	-91.59%	-73.08%

In the previous week, Voyager Therapeutics had 2 more articles in the media than Hyperion DeFi. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.88 beat Voyager Therapeutics' score of 0.45 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperion DeFi	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, suggesting that its stock price is 149% more volatile than the broader market.

Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 336.51%. Hyperion DeFi has a consensus target price of $6.95, suggesting a potential upside of 123.47%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hyperion DeFi has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$36.49M	6.26	-$119.72M	-$1.97	N/A
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Voyager Therapeutics beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Keros Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Hyperion DeFi had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 2 mentions for Hyperion DeFi and 1 mentions for Keros Therapeutics. Hyperion DeFi's average media sentiment score of 0.88 beat Keros Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperion DeFi has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hyperion DeFi presently has a consensus target price of $6.95, suggesting a potential upside of 123.47%. Keros Therapeutics has a consensus target price of $20.40, suggesting a potential upside of 81.17%. Given Hyperion DeFi's higher probable upside, equities analysts plainly believe Hyperion DeFi is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Keros Therapeutics has higher revenue and earnings than Hyperion DeFi. Keros Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A

Hyperion DeFi has a beta of 2.49, suggesting that its share price is 149% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

Keros Therapeutics beats Hyperion DeFi on 9 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Avidity Biosciences?

Hyperion DeFi (NASDAQ:HYPD) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

25.8% of Hyperion DeFi shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hyperion DeFi has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
Avidity Biosciences	$36.68M	6.37	-$322.30M	-$0.97	N/A

Hyperion DeFi presently has a consensus target price of $6.95, suggesting a potential upside of 123.47%. Avidity Biosciences has a consensus target price of $66.81, suggesting a potential upside of 389.47%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

In the previous week, Hyperion DeFi had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 2 mentions for Hyperion DeFi and 0 mentions for Avidity Biosciences. Hyperion DeFi's average media sentiment score of 0.88 beat Avidity Biosciences' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Avidity Biosciences	Neutral

Hyperion DeFi has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Hyperion DeFi has a beta of 2.49, meaning that its stock price is 149% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Summary

Hyperion DeFi beats Avidity Biosciences on 9 of the 17 factors compared between the two stocks.

How does Hyperion DeFi compare to Unicycive Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Hyperion DeFi has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 41 more articles in the media than Hyperion DeFi. MarketBeat recorded 43 mentions for Unicycive Therapeutics and 2 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.88 beat Unicycive Therapeutics' score of -0.20 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Hyperion DeFi's return on equity of -91.59% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Unicycive Therapeutics has lower revenue, but higher earnings than Hyperion DeFi. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
Unicycive Therapeutics	$680K	230.80	-$26.56M	-$2.21	N/A

Hyperion DeFi currently has a consensus price target of $6.95, suggesting a potential upside of 123.47%. Unicycive Therapeutics has a consensus price target of $27.40, suggesting a potential upside of 378.18%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Unicycive Therapeutics beats Hyperion DeFi on 8 of the 15 factors compared between the two stocks.

How does Hyperion DeFi compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, ALX Oncology and ALX Oncology both had 2 articles in the media. Hyperion DeFi's average media sentiment score of 0.88 beat ALX Oncology's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperion DeFi	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ALX Oncology currently has a consensus target price of $4.60, suggesting a potential upside of 122.22%. Hyperion DeFi has a consensus target price of $6.95, suggesting a potential upside of 123.47%. Given Hyperion DeFi's higher possible upside, analysts plainly believe Hyperion DeFi is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, suggesting that its stock price is 149% more volatile than the broader market.

Hyperion DeFi has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A

Hyperion DeFi's return on equity of -91.59% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Hyperion DeFi	N/A	-91.59%	-73.08%

Summary

Hyperion DeFi beats ALX Oncology on 8 of the 13 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPD vs. The Competition

Export

Metric	Hyperion DeFi	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$47.14M	$431.50M	$7.16B	$12.48B
Dividend Yield	N/A	3.88%	2.66%	6.52%
P/E Ratio	-0.31	3.09	28.02	24.70
Price / Sales	58.21	6,669.11	540.37	99.46
Price / Cash	N/A	13.13	49.26	57.09
Price / Book	0.66	88.67	10.96	6.46
Net Income	-$45.31M	-$96.07M	$3.57B	$337.01M
7 Day Performance	2.81%	0.17%	2.12%	1.69%
1 Month Performance	4.01%	2.10%	5.25%	3.81%
1 Year Performance	-80.51%	68.02%	33.29%	23.90%

Hyperion DeFi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPD Hyperion DeFi	3.4239 of 5 stars	$3.11 flat	$6.95 +123.5%	-80.5%	$47.14M	$810K	N/A	40	Analyst Forecast
VYGR Voyager Therapeutics	2.9489 of 5 stars	$3.70 -0.7%	$16.50 +346.5%	+15.2%	$223.44M	$36.49M	N/A	100	News Coverage
KROS Keros Therapeutics	2.7087 of 5 stars	$11.27 +2.6%	$20.40 +81.1%	-15.5%	$222.95M	$244.06M	N/A	100	Gap Down
RNA Avidity Biosciences	1.9465 of 5 stars	$13.00 +0.5%	$66.81 +413.9%	-53.1%	$222.38M	$36.68M	N/A	190
UNCY Unicycive Therapeutics	3.2652 of 5 stars	$8.11 +3.0%	$24.75 +205.2%	+23.6%	$222.33M	$680K	N/A	9	Trending News Analyst Forecast Options Volume Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperion DeFi (HYPD) Competitors

HYPD vs. VYGR, KROS, RNA, UNCY, and ALXO

How does Hyperion DeFi compare to Voyager Therapeutics?

Summary

How does Hyperion DeFi compare to Keros Therapeutics?

Summary

How does Hyperion DeFi compare to Avidity Biosciences?

Summary

How does Hyperion DeFi compare to Unicycive Therapeutics?

Summary

How does Hyperion DeFi compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperion DeFi (HYPD) Competitors

HYPD vs. VYGR, KROS, RNA, UNCY, and ALXO

How does Hyperion DeFi compare to Voyager Therapeutics?

Is VYGR or HYPD more profitable?

Does the media prefer VYGR or HYPD?

Which has more risk and volatility, VYGR or HYPD?

Do analysts prefer VYGR or HYPD?

Which has preferable earnings & valuation, VYGR or HYPD?

Do insiders & institutionals have more ownership in VYGR or HYPD?

Summary

How does Hyperion DeFi compare to Keros Therapeutics?

Does the media prefer HYPD or KROS?

Is HYPD or KROS more profitable?

Do institutionals & insiders have more ownership in HYPD or KROS?

Do analysts prefer HYPD or KROS?

Which has higher earnings and valuation, HYPD or KROS?

Which has more risk & volatility, HYPD or KROS?

Summary

How does Hyperion DeFi compare to Avidity Biosciences?

Do insiders and institutionals have more ownership in HYPD or RNA?

Which has stronger earnings & valuation, HYPD or RNA?

Do analysts rate HYPD or RNA?

Does the media favor HYPD or RNA?

Is HYPD or RNA more profitable?

Which has more volatility and risk, HYPD or RNA?

Summary

How does Hyperion DeFi compare to Unicycive Therapeutics?

Which has more risk & volatility, HYPD or UNCY?

Do insiders & institutionals have more ownership in HYPD or UNCY?

Does the media favor HYPD or UNCY?

Is HYPD or UNCY more profitable?

Which has better earnings and valuation, HYPD or UNCY?

Do analysts rate HYPD or UNCY?

Summary

How does Hyperion DeFi compare to ALX Oncology?

Does the media prefer ALXO or HYPD?

Do institutionals and insiders hold more shares of ALXO or HYPD?

Do analysts rate ALXO or HYPD?

Which has more volatility & risk, ALXO or HYPD?

Which has stronger valuation and earnings, ALXO or HYPD?

Is ALXO or HYPD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools